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How compelling is the data for EBV being a trigger for systemic lupus and 
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This	 study	 is	 the	 first	 to	 compare	 the	humoral	 responses	 (IgM,	 IgG	 and	 IgA)	 to	 early	 antigens	of	 the	
three	HHVs:	EBV,	CMV	and	HHV6	 in	SLE	patients	and	HCs.	SLE	patients	had	an	 increased	response	to	


























By	 the	 use	 of	 a	 mouse	 model	 with	 a	 conditional	 expression	 of	 LMP2A	 in	 B-cells,	 this	 study	





a	 significantly	 reduced	 fraction	 of	 functioning	 EBV-specific	 T-cells	 in	 SLE	 patients	 compared	 to	 HCs.	
























This	 study	 investigates	 the	 role	 of	 VZV	 in	 SLE,	 and	 show	an	 increased	 humoral	 response	 (IgG)	 and	 a	






































A	 study	 demonstrating	 an	 uncontrolled	 latent	 EBV	 infection	 in	MS	 patients	 by	 showing	 significantly	
increased	EBV	DNA	loads	in	PBMCs	that	were	inversely	associated	with	vitamin	D	levels.	Furthermore,	


























Table 1.  SLE characteristics [2] and predisposing immuno-deficiencies [1,3,4] 
Table 2.  EBV characteristics and associated diseases [7,8,9] 
Figure 1. Epstein Barr virus 
EBV	 consists	 of	 a	 dsDNA	 genome	within	 a	 capsid	 surrounded	 by	 tegument	within	 a	 lipid	 envelope	with	
surface	 glycoproteins.	 EBV	 is	 transmitted	 via	 saliva	 and	 enters	 epithelial	 cells	 and	 B-cells.	 EBV	 shifts	
between	a	resting	latent	state	in	memory	B-cells	with	a	limited	expression	of	genes	(EBNAs	and	LMPs)	and	
reactivation	to	lytic	cycle	with	expression	of	immediate	early	(IE)	antigens	(transcription	factors),	early	(E)	
antigens	 (including	 EBV-EA/D)	 and	 replication	 of	 the	 viral	 genome	 and	 subsequent	 expression	 of	 late	 (L)	
antigens	 (structural	 proteins	 including	 EBV-p23)	 resulting	 in	 production	 and	 release	 of	 new	 virus.	 [7,8]	
(electronmicrograph:	http://www.sciencedaily.com/releases/2005/07/050725065240.htm)	
Figure 2. Gene – environment interactions in the development of SLE with an emphasis on the 
role of EBV 
Timeline	 showing	 the	 immuno-profile	 and	 environmental	 elements	 affecting	 the	 development	 of	 SLE	 in	
genetically	predisposed	individuals	with	certain	immuno-deficiencies.	The	primary	infection	with	EBV	leads	
to	 production	 of	 EBV-directed	 antibodies	 and	 generation	 of	 EBV-specific	 T-cells.	 Over	 time	 (and	 with	
multiple	 reactivations)	 the	 quantity	 of	 EBV-specific	 T-cells	 decreases	 and	 the	 latent	 infection	 gets	 even	
harder	 to	 control	 resulting	 in	 increasing	 number	 of	 disseminated	 EBV-infected	 cells	 and	 eventually	
production	 of	 autoantibodies	 triggered	 by	 the	 cumulative	 waste	 load	 and	 further	 development	 of	 SLE	
symptoms.	 The	 EBV-specific	 antibodies	 stay	 at	 high	 titres	 reflecting	 the	 increased	 antigen	 load	 and	
attempts	to	control	the	numerous	reactivations	as	compensation	for	lack	of	cell-mediated	control.		
	
